Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 6/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.73 |
| ▸ | MAOB | P27338 | 5/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17375871 | 0.92 | PDGFRB (0.62) | PDGFRBPDGFRAMAOBHSD17B2NPC1 | |
| SCHEMBL18988150 | 0.89 | PDGFRB (0.60) | PDGFRBPDGFRAMAOBHSD17B2NPC1 | |
| SCHEMBL18987989 | 0.89 | PDGFRB (0.60) | PDGFRBPDGFRAMAOBHSD17B2NPC1 | |
| SCHEMBL13386997 | 0.89 | PDGFRB (0.60) | PDGFRBPDGFRAMAOBHSD17B2NPC1 | |
| SCHEMBL18988236 | 0.89 | PDGFRB (0.60) | PDGFRBPDGFRAMAOBHSD17B2NPC1 | |
| SCHEMBL20474201 | 0.85 | PDGFRB (0.56) | PDGFRBPDGFRA | |
| SCHEMBL8502397 | 0.84 | PDGFRB (1.00) | PDGFRBPDGFRA | |
| SCHEMBL18987618 | 0.82 | PDGFRB (0.52) | PDGFRBPDGFRAMAOBNPC1RAB9A | |
| SCHEMBL7227312 | 0.81 | MAOB (0.54) | PDGFRBPDGFRAMAOBNPC1RAB9A | |
| SCHEMBL28448861 | 0.81 | PDGFRB (0.51) | PDGFRBPDGFRAMAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227355-B2 | Quinoline derivatives and preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2019-03-12 | — | — | US | disclosed |
| US-10227355-B2 | Quinoline derivatives and preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2019-03-12 | — | — | US | disclosed |
| US-20180237448-A1 | NOVEL QUINOLINE DERIVATIVES AND PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237448-A1 | NOVEL QUINOLINE DERIVATIVES AND PREPARATION THEREOF | ABL1, FLT3, MAP3K7 | PDGFRB 278/4885PDGFRA 263/4885MAOB 478/4885 |
| US-10227355-B2 | Quinoline derivatives and preparation thereof | ABL1, FLT3, MAP3K7 | PDGFRB 248/4885PDGFRA 239/4885MAOB 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.